Alternatives to Voydeya If You Can't Fill Your Prescription

Voydeya (danicopan) is a breakthrough oral medication for PNH patients with extravascular hemolysis (EVH), but its restricted access, REMS requirements, complex prior authorization process, and specialty-only dispensing can create significant barriers. If you are currently unable to fill your Voydeya prescription, it is important to know your options. This guide covers the FDA-approved alternatives for PNH treatment in 2026 — and how to discuss them with your hematologist.

Important note: Never stop or switch PNH medications without talking to your hematologist. PNH is a serious, life-threatening condition and medication changes require careful clinical supervision.

Why Voydeya Access Can Be Challenging

As we explain in detail in our article on why Voydeya is so hard to find, access barriers include: mandatory VOYDEYA REMS enrollment, vaccination requirements that must be completed at least 2 weeks before the first dose, prior authorization from insurance (which takes 5–14+ business days), and dispensing exclusively through Onco360 specialty pharmacy. If these hurdles are causing delays, knowing your alternatives is critical.

Understanding the PNH Treatment Landscape

PNH treatments fall into several categories based on where in the complement pathway they act:

C5 inhibitors (eculizumab, ravulizumab, crovalimab): Block intravascular hemolysis (IVH) but may leave EVH uncontrolled in some patients

Proximal complement inhibitors (pegcetacoplan, iptacopan, danicopan): Act upstream in the pathway to address both IVH and EVH

Voydeya is unique in that it is the only FDA-approved add-on to an existing C5 inhibitor — rather than a replacement for it. If you cannot access Voydeya specifically, your doctor may consider switching your entire treatment regimen to a different proximal inhibitor.

Alternative 1: Empaveli (Pegcetacoplan) — C3 Inhibitor

Empaveli (pegcetacoplan) is a subcutaneous (under-the-skin) injection taken twice weekly. It is a C3 inhibitor that acts upstream of C5, addressing both intravascular and extravascular hemolysis. It is administered at home using an infusion pump and is generally considered a C5-inhibitor replacement (not an add-on). It may be an option if you are switching away from eculizumab or ravulizumab entirely.

Route: Subcutaneous infusion, twice weekly at home

Target: C3 (proximal complement inhibitor)

Addresses: Both IVH and EVH

Alternative 2: Fabhalta (Iptacopan) — Factor B Inhibitor

Fabhalta (iptacopan) is an oral capsule taken twice daily and was approved by the FDA in December 2023. Like Voydeya, it targets the alternative complement pathway — but at Factor B rather than Factor D. Fabhalta is approved as a standalone therapy (not as an add-on), making it a potential replacement for C5 inhibitor regimens. It's the other first-in-class proximal oral complement inhibitor for PNH.

Route: Oral capsule, twice daily

Target: Complement Factor B (proximal alternative pathway)

Key difference from Voydeya: Monotherapy (replaces C5 inhibitor) vs. Voydeya's add-on status

Alternative 3: Ultomiris (Ravulizumab) — C5 Inhibitor

Ultomiris (ravulizumab) is one of the two C5 inhibitors that Voydeya is designed to be added on top of. If you are not yet on a C5 inhibitor, Ultomiris — given as an IV infusion every 8 weeks — may be the appropriate starting point. For patients with ongoing EVH despite Ultomiris, Voydeya would then be considered as an add-on.

Alternative 4: Soliris (Eculizumab) — C5 Inhibitor

Soliris (eculizumab) was the original FDA-approved treatment for PNH and remains an active option. Given IV every two weeks, it was the standard of care before newer agents were available. Biosimilars of eculizumab (Epysqli, Bkemv) are now available, which may reduce the cost burden compared to brand-name Soliris.

Comparing Your Options: A Quick Summary

Voydeya (danicopan): Oral tablet, three times daily. Add-on only. Factor D inhibitor. REMS required. Only for patients already on C5 inhibitors with ongoing EVH.

Fabhalta (iptacopan): Oral capsule, twice daily. Monotherapy option. Factor B inhibitor. REMS required.

Empaveli (pegcetacoplan): Subcutaneous infusion, twice weekly. Monotherapy option. C3 inhibitor. REMS required.

Ultomiris (ravulizumab): IV infusion, every 8 weeks. Monotherapy standard of care. C5 inhibitor. REMS required.

Soliris (eculizumab): IV infusion, every 2 weeks. Monotherapy standard of care. C5 inhibitor. Biosimilars available.

Talk to Your Hematologist About Switching

Any switch in PNH therapy must be managed by a hematologist, as stopping complement inhibition — even briefly — can trigger life-threatening hemolysis. If you need help finding a hematologist who can manage your PNH therapy, see our guide to finding a doctor who can prescribe Voydeya near you.

If you're working through prescription access challenges, medfinder is here to help you navigate specialty medication availability — submit your details and we'll call pharmacies on your behalf to determine where your medication can be filled.